CMS will revisit its 2007 non-coverage determination (NCD) of vagus nerve stimulation (VNS) for treatment-resistant depression (TRD), and the petitioner, Livanova plc of London, said that a "significant body of new evidence has emerged" since the 2007 NCD. Just where CMS will land on this coverage request is unclear, but there may be 3 million patients or more in the U.S. who would be eligible for the device, should CMS cover VNS for this indication. Read More
